An observational study in Diabetic Peripheral Neuropathic Pain, sponsored by Daiichi Sankyo. Completed at 43 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Daiichi Sankyo · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Neuralgia with a site in China — 17 open to participants now, 17 under way, 1 of them phase 3. Neuralgia · China.
Among the 41 studies in Neuralgia with a site in China, this one is the 3rd largest by enrollment of the 10 observational ones that give a count, is one of 7 that started in 2025, is one of 10 observational ones, and was the 29th registered.
1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.
Browse Neuralgia studies →17 of the 41 studies in Neuralgia with a site in China are open now. Recruiting first, the newest first:
Zhejiang Hanmai Pharmaceutical Technology Co., Ltd. · Sites in China
Ages 18+
Nanchong Central Hospital · Sites in China
Ages 18+
Shandong Suncadia Medicine Co., Ltd. · Sites in China
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 155 Neuralgia studies recruiting now, 79 (51%) set no upper age limit and 44 (28%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 6 · Phase 4 2
First in 2006; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 721 is above the median of 102 across 232 observational studies indexed under Neuralgia.
Median enrollment 147 across the 31 interventional studies, 300 across the 10 observational. Of the 20 that completed or were terminated, 3 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 41 have an industry lead sponsor. The 10 most frequent:
Daiichi Sankyo is the lead sponsor of 322 studies on the registry; 36 are open to participants now.
Of its 51 completed or terminated interventional studies of FDA-regulated products, 38 (75%) have results posted.
Daiichi Sankyo has 6 studies filed under Neuralgia — fewer than ten, so there is no comparison to draw.
5 of the studies in Neuralgia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06766916Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityCrisugabalin for Radiotherapy-Related Neuropathic Pain | 2026-11-30 |
| NCT06596681Beijing Tiantan HospitalA Study of the Safety and Tolerability of GA in the Treatment of Patients With Refractory Neuropathic Pain | 2026-12-31 |
| NCT07740707Nanchong Central HospitalShort-term SCS for Refractory Diabetic Foot Neuropathic Pain | 2027-03-01 |
| NCT07148388Second Affiliated Hospital, School of Medicine, Zhejiang UniversityAccelerated Intermittent Theta Burst Stimulation (AiTBS)on Neuropathic Pain | 2027-09-01 |
| NCT07699770Tang-Du HospitalCrisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial | 2027-10-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 41 studies in Neuralgia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety and effectiveness of mirogabalin in adult patients with diabetic peripheral neuropathic pain (DPNP) in real-world clinical practice setting in China.
Mirogabalin has been approved in China for the treatment of DPNP. Although there is evidence of the safety and efficacy of mirogabalin, there is a lack of real-world evidence on its safety and effectiveness to inform decision-making among a more diverse patient population in real-world clinical practice, such as patients with moderate or severe renal impairment; patients with more complications, comorbidities, and treatments; and patients with different severity of pain.
This study aims to collect safety and effectiveness data to guide physicians in the clinical use of mirogabalin for the treatment of patients with DPNP in the real-world clinical practice setting.
Eligible patients diagnosed with DPNP and newly treated with mirogabalin will be consecutively enrolled in this study and followed up until the end of 15-week observation period, the end of 1-week observation period after the discontinuation of mirogabalin, withdrawal of consent, loss to follow-up, or study closure, whichever occurs first, to collect and evaluate patients' outcomes.
Inclusion Criteria:
Patients must meet all the following criteria to be eligible for this study.
Patients who meet any of the following criteria will be excluded from this study.
Patients who received pregabalin, gabapentin, crisugabalin, or any other DPNP analgesic medications* within 7 days prior to ICF signed.
*Other DPNP analgesic medication includes TCAs (amitriptyline, nortriptyline), SNRIs (duloxetine, venlafaxine), antiepileptics (carbamazepine), opioids (tapentadol, tramadol).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients diagnosed with DPNP and newly treated with mirogabalin.
Other: No Drug
This is an non-interventional, observational study. No drug will be provided or administered as part of this protocol; however, participants on mirogabalin will be enrolled in this study.
Proportion of participants with any treatment related adverse events (TRAEs)
An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
Time frame: Baseline to Week 14
Time-to-onset of somnolence, dizziness, weight gain, and peripheral edema
For time-to-event variables, the median time, Q1 and Q3 as well as 95% CI will be estimated.
Time frame: Baseline to Week 14
Symptom duration of somnolence, dizziness, weight gain, and peripheral edema
For time-to-event variables, the median time, Q1 and Q3 as well as 95% CI will be estimated.
Time frame: Baseline to Week 14
Proportion of participants with TEAEs, serious TEAEs, TRAEs leading to study treatment discontinuation
An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
Time frame: Baseline to Week 14
Change from baseline in VAS pain
The VAS is used for the participant to rate average pain intensity of past 24 hours on a 100 mm-long horizontal line, where 0 mm = no pain and 100 mm = worst possible pain. Reductions in VAS pain scores indicate better clinical outcome.
Time frame: Week 14
Proportion of participants achieving 30% and 50% pain relief (reduction in VAS score compared to baseline)
The VAS is used for the participant to rate average pain intensity of past 24 hours on a 100 mm-long horizontal line, where 0 mm = no pain and 100 mm = worst possible pain. Reductions in VAS pain scores indicate better clinical outcome.
Time frame: Baseline to Week 14
Time to achieve 30% pain relief or 50% pain relief (reduction in VAS score compared to baseline)
The VAS is used for the participant to rate average pain intensity of past 24 hours on a 100 mm-long horizontal line, where 0 mm = no pain and 100 mm = worst possible pain. Reductions in VAS pain scores indicate better clinical outcome.
Time frame: Baseline to Week 14
Change from baseline in Douleur Neuropathique 4 questions (DN4) score
DN4 will be assessed by the investigator after ICF signed and prior to the first administration of mirogabalin as baseline, when participants return to the clinical site during treatment period of mirogabalin, and at the end of mirogabalin treatment. Each "yes" answer is assigned 1 point, and a total score is calculated. A score of 4 or higher indicates a higher likelihood of neuropathic pain (eg. worse clinical outcome), while a score below 3 suggests it is less likely (eg. better clinical outcome).
Time frame: Week 14
Patient Global Impression of Change (PGIC)
Participants will provide a self-assessment using the 7-point scale via ePRO at the end of mirogabalin treatment: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse. Lower PGIC scores indicate better clinical outcome.
Time frame: Week 14
Change from baseline in EuroQol 5-Dimension 5-level (EQ-5D-5L)
The self-administered EQ-5D-5L includes the EQ-5D and the EQ VAS. EQ-5D comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1=no problems, 2=slight problems, 3-moderate problems, 4=severe problems and 5=extreme problems. The patient is asked to indicate his/her health state in each of the five dimensions, resulting in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. Lower 5-digit numbers indicates better clinical outcome (ie, health state). The EQ VAS records the patient's self-rated health on a vertical VAS where the endpoints are labelled '100 - The best health you can imagine' and '0 - The worst health you can imagine'. Higher EQ VAS scores indicate better clinical outcome/health.
Time frame: Week 14
Plan to share: No
Ran from Jan 2025 to primary completion in Apr 2026, 14 months.
Of 88 observational studies under Neuralgia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's 14 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Jul 2026 → Apr 2026 and completion Jul 2026 → Apr 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.